ArticlePloS one2025
Pharmaceutical expenditure changes under the volume-based procurement policy: Effects and influencing factors.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Governance absorption of volume-based procurement: study of dual-track implementation in a public hospital.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the impact of China's volume-based procurement (VBP) policy on the expenditure of both policy-covered and uncovered drugs, and to identify the elements that contribute to drug expenditure changes under VBP policy.
methodsUsing national drug procurement data of public medical institutions, this study included 25 policy-covered VBP drugs and 99 policy-uncovered alternative drugs as samples, seven "4+7" pilot cities and eight "4+7" expansion provinces as observation regions. Time-varying difference-in-difference (DID) model was applied to quantify policy impact on drug expenditures. The drug expenditure index decomposition method was employed to analyze the determinants of drug expenditure changes following VBP policy.
resultsThe expenditure of VBP drugs significantly decreased by 42.19% after VBP policy (β = -0.55, p < 0.001), while alternative drugs increased by 11.52% (β = -0.11, p < 0.001), with a significant reduction in the overall expenditure of observed drugs (β = -0.05, p < 0.001). The decrease of VBP drug expenditures showed a trend of tertiary hospital (β = -0.64, p < 0.001) > secondary hospital (β = -0.57, p < 0.001) > primary healthcare centers (β = -0.39, p < 0.001). The index decomposition showed that manufacturer structure index (IM) decline was the primary driver for expenditure reduction of policy-covered drugs, with the IM decrease of 54.17% in pilot cities and 40.86% in expansion regions. The secondary driver was the price index (IP), with a decline of 31.68% in pilot cities and 36.08% in expansion regions. The restraining factor was the quantity index (IQ), increasing by 92.54% in pilot cities and 52.04% in expansion regions. IQ also drove the increase in alternative drug expenditures, increasing by 95.56% in pilot cities and 32.76% in expansion regions.
conclusionVBP policy effectively promoted the decline of total drug expenditures, primarily through manufacturer-level market displacement and the absolute price reduction. However, the "spillover effect" of alternative drugs weakened the overall effect on cost control. Strengthening holistic governance and improving the quality and intensiveness of drug use are important directions for future policy perfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.